Hoffmann-La Roche says it will build monoclonal antibody plants at Basel and Penzberg.

Hoffmann-La Roche says it will build monoclonal antibody plants at Basel and Penzberg, Switzerland, at a costliness of about SF400 million ($326 million) each, to suited "steadily growing demand" for its biologic drags. Construction will take three years,

Want to read the whole article? You can purchase it here. It's quick and easy....